Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate UpdateGlobeNewsWire • 02/11/21
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate UpdateGlobeNewsWire • 02/04/21
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson DiseaseGlobeNewsWire • 01/21/21
Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy StudiesGlobeNewsWire • 01/08/21
Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare ConferenceGlobeNewsWire • 01/05/21
Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis ImperfectaGlobeNewsWire • 12/17/20
Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson DiseaseGlobeNewsWire • 12/09/20
GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman SyndromeGlobeNewsWire • 12/05/20
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare DiseasesGlobeNewsWire • 11/09/20
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 11/02/20
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/28/20